Cetuximab is a monoclonal antibody with activity against colorectal cancers that overexpress epidermal growth factor receptor. This agent blocks epidermal growth factor receptor signaling and ...

Cetuximab therapy was started on the day radiation therapy began with a loading dose of 400 mg/m 2 in the first week, and then 250 mg/m 2 /week for the successive radiation weeks. One cycle of ...

Johnson & Johnson (NYSE:JNJ) has announced that the U.S. FDA has declined to approve an injectable version of its cancer ...

Indeed, results from the FLEX trial demonstrate that cetuximab in combination with platinum-based chemotherapy is a new treatment strategy for patients with advanced NSCLC. The EGFR pathway has an ...

The application includes an every-three-week (Q3W) amivantamab regimen in combination with carboplatin and pemetrexed. This would be for adult patients with advanced non-small cell lung cancer (NSCLC) ...

CRYSTAL: Cetuximab Combined with Irinotecan in First Line Therapy for Metastatic Colorectal Cancer; HR: Hazard ratio; FOLFIRI: Folinic acid and fluorouracil-based regimen containing irinotecan ...